RemeGen reports RMB 3.84 billion cash balance as of June 30, 2026 in H1 presentation
PUBT·- RemeGen reported a cash balance of RMB 3.84 billion and domestic drug sales of RMB 1.4 billion for H1 2026. - The company highlighted commercial portfolios like telitacicept and disitamab vedotin, alongside global partnerships with potential value exceeding USD 12 billion. - Key clinical updates included Phase 3 readouts for telitacicept, notably showing a 55% placebo-adjusted 24-hour UPCR reduction in the IgAN study.Pharmaceutical Stocks To Watch Now - August 23rd
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, McKesson, Abbott Laboratories, and Pfizer. - These publicly traded companies engage in researching, developing, manufacturing, and selling medicines and healthcare products worldwide. - While offering growth potential from successful drug launches, these stocks also carry inherent risks such as clinical trial failures and regulatory decisions.Best Pharmaceutical Stocks To Watch Today - August 21st
Market Beat·- MarketBeat identified seven pharmaceutical stocks with the highest dollar trading volume to watch, including Eli Lilly, Merck, Johnson & Johnson, AbbVie, Pfizer, Abbott Laboratories, and Jupiter Neurosciences. - These publicly traded companies operate globally in discovering, developing, manufacturing, and selling prescription and over-the-counter medicines across diverse therapeutic areas. - While these pharmaceutical stocks offer growth potential through successful drug approvals and strong sales, they also carry inherent risks related to clinical trials, regulatory decisions, patents, and pricing pressures.